A detailed financial and strategic comparison of Anthem Biosciences with Syngene International, Sai Life Sciences, Cohance Lifesciences, and Divi’s Laboratories — India’s leading listed Contract Research and Development/Manufacturing Organisations (CRDMOs/CDMOs).
🏢 Anthem Biosciences: Company Overview
Anthem Biosciences is a fast-growing Indian CRDMO with integrated capabilities across the drug development lifecycle, spanning New Chemical Entities (NCEs) and New Biological Entities (NBEs). With over 550 customers across 44+ countries and more than 8,000 unique projects, the company serves some of the world’s leading pharmaceutical and biotech firms.
In FY 2025, Anthem clocked a revenue of INR 1,844.55 Cr and stood out for its fastest revenue growth among Indian and global peers.
Anthem Biosciences Peers Selection Criteria
Peers have been selected based on:
- Business similarity (CRAMS/CDMO model)
- Presence in regulated markets (US, EU, Japan)
- Comparable size, growth trajectory, and clientele
Peers considered:
- Syngene International
- Sai Life Sciences
- Cohance Lifesciences
- Divi’s Laboratories
📈 Anthem Biosciences Peer Comparison: Financial Performance Snapshot (FY25)
| Metric | Anthem | Syngene | Sai Life | Cohance | Divi’s |
|---|---|---|---|---|---|
| Revenue (INR Cr) | 1,844.55 | 3,642.40 | 1,694.57 | 1,197.58 | 9,360.00 |
| EPS (INR) | 8.07 | 12.34 | 8.61 | 10.45 | 82.53 |
| P/E (X) | 66.91–70.63 | 53.3 | 94.1 | 147 | 82.8 |
| ROE (%) | 20.82 | 10.5 | 10.9 | 14.1 | 15.4 |
| ROCE (%) | 27.64 | 13.5 | 13.9 | 16.8 | 20.4 |
| Net Margin (%) | 24.46 | 13.0 | 10.6 | 22.1 | 23.4 |
| Debt/Equity | 0.05 | 0.12 | 0.13 | 0.16 | 0.00 |
| Book Value (INR) | 43.10 | 117 | 104 | 66.6 | 564 |
🔍 Valuation Analysis
Anthem’s implied P/E ratio of 66.9–70.6x positions it at a premium to Syngene (53x) but below Sai Life (94x) and Cohance (147x). While it may appear expensive compared to its large peers, it reflects high growth visibility, strong margins, and superior return ratios.
💰 Profitability and Return Metrics
- ROE: Anthem leads the peer group at 20.82%, well above Syngene (10.5%) and comparable to Divi’s (15.4%).
- ROCE: At 27.64%, Anthem significantly outperforms all peers, including Divi’s (20.4%).
- EBITDA Margin: Anthem’s margin stands at 36.81%, higher than Syngene (26–28%) and in line with Divi’s (30–32%), supporting operational efficiency.
These ratios highlight Anthem’s capital efficiency and ability to generate shareholder value.
💹 Growth Trajectory & Market Positioning
🔼 Revenue Growth:
Anthem recorded an impressive CAGR of ~32% from FY23 to FY25, compared to:
- Syngene: ~4.4%
- Sai Life: ~15.7%
- Cohance: ~13.9%
- Divi’s: ~19.3%
This makes Anthem the fastest-growing CRDMO/CDMO among its Indian peers.
📈 R&D & Strategic Strength:
- Anthem is involved in 242 active projects, with 16 in late-phase and 13 in commercial manufacturing.
- Its specialization in ADCs, RNAi, peptides, oligonucleotides and association with blockbuster molecules (USD 11.3B in 2024, expected USD 21.4B by 2029) adds significant IP leverage.
🏦 Balance Sheet & Capital Structure
- Anthem’s Debt/Equity is just 0.05, reflecting a conservative capital structure.
- Divi’s is debt-free, while others like Cohance and Sai Life operate with modest leverage (0.12–0.16).
Summary
| Company | Strategic Strength |
|---|---|
| Anthem Biosciences | NCE/NBE expertise, high-growth IP-linked projects, strong EBITDA & ROE |
| Syngene | Legacy CRO/CDMO with broad customer base, slower revenue growth |
| Sai Life Sciences | Mid-size focused CRO, high valuations, moderate margins |
| Cohance | High-end intermediates & CDMO, but expensive with thin historical growth |
| Divi’s Labs | API & nutraceutical giant, high brand equity, cash-rich |
✅ Conclusion: Where Anthem Stands
Anthem Biosciences, with its strong growth trajectory, capital-efficient model, and healthy margins, emerges as a standout among peers, especially in terms of:
- ROE/ROCE Leadership
- Revenue Growth Leadership
- Late-phase project engagement
- Global footprint across 44 countries
While its P/E multiples reflect a premium, these are justified by its profitability, scalability, and strong market positioning in specialised drug segments.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.